SAN DIEGO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today announced that Richard Lowenthal, Co-Founder, President and CEO and Eric Karas, Chief Commercial Officer will participate in presentations at the Cantor Global Healthcare Conference and the Stifel Immunology and Inflammation Summit in September.
Details outlined below.
Cantor Global Healthcare Conference
Presentation (Fireside Chat): Wednesday, September 3, 2025
Time: 3:55 p.m. ET
Location: New York
A live webcast of the presentation will be available here.
Stifel Immunology and Inflammation Summit
Presentation: Monday, September 15, 2025
Time: 12:00 p.m. ET
Location: Virtual
A live webcast of the presentation will be available here.
To access the live and archived webcasts for the investor conferences, please visit the Events & Presentations page in the “Investors & Media” section of the Company’s website. A replay of each of the webcasts will be available for 30 days following the event.
About ARS Pharmaceuticals, Inc.
ARS Pharma is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing neffy® (trade name EURneffy® in the EU), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult patients and pediatric patients 4 years of age and older who weigh 33 lbs. or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.
Investor Contact:
Justin Chakma, ARS Pharma
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact:
Christy Curran, Sam Brown Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
615.414.8668
| Last Trade: | US$9.96 |
| Daily Change: | -0.07 -0.70 |
| Daily Volume: | 2,776,400 |
| Market Cap: | US$984.350M |
September 08, 2025 August 13, 2025 | |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
